Pfizer (PFE) has an average broker rating of 1.86, which is interpreted as a Buy, as rated by 14 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 6 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Pfizer (PFE) : 13 investment research analysts covering Pfizer (PFE) have an average price target of $39.46 for the near short term. The highest target price given by the Brokerage Firm to the stock is $54 and the lowest target is $33 for the short term. Analysts expect the variance to be within $5.39 of the average price.
For the current week, the company shares have a recommendation consensus of Buy. Pfizer (NYSE:PFE): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $35.13 and $35.10 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $35.28. The buying momentum continued till the end and the stock did not give up its gains. It closed at $35.15, notching a gain of 0.06% for the day. The total traded volume was 13,384,075 . The stock had closed at $35.13 on the previous day.
In a related news,The officer (Executive Vice President) of Pfizer Inc, Damelio Frank A sold 100,000 shares at $34.49 on May 26, 2016. The Insider selling transaction had a total value worth of $3,449,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.